DLX-105
DLX-105 is a human monoclonal antibody (mAb) targeting TNFSF2/TNFa. DLX-105 reduces skin epidermal thickness and the expression of K16 and Ki67. DLX-105 down-regulates the mRNA levels of IL-17, TNF-α, IL-23p19, IL-12p40, and IFN-γ. DLX-105 can be used in psoriasis research[1].
Product Specifications
UNSPSC
12352203
Target
IFNAR; Interleukin Related; TNF Receptor
Related Pathways
Apoptosis; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
[DLX-105]
References & Citations
[1]Tsianakas A, et al. The single-chain anti-TNF-α antibody DLX105 induces clinical and biomarker responses upon local administration in patients with chronic plaque-type psoriasis. Exp Dermatol. 2016 Jun;25 (6) :428-33.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS6202195-01 0.1 mL
NRBP2 (Nuclear Receptor-binding Protein 2, DKFZp434P086, MGC138699, PP9320, Transformation-related Gene 16 Protein, TRG16, TRG-16) (MaxLight 490)
Ask
View Details